Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter[1] It is an analog of avibactam.

The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023.

[1]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.